Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present H. Lundbeck A/S (OTC: HLUYY).

Full DD Report for HLUYY

You must become a subscriber to view this report.


Recent News from (OTC: HLUYY)

FDA tentatively OKs Aquestive's Sympazan for severe type of childhood epilepsy; shares up 1%
Aquestive Therapeutics ( AQST +1% ) is up on below-average volume on the heels of tentative FDA approval for Sympazan (clobazam) oral film for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a severe form of childhood epilepsy, in patients at least two...
Source: SeekingAlpha
Date: August, 31 2018 15:16
After A Wild Party, Lundbeck Wakes To A Nasty Hangover
I would argue that the reaction to H. Lundbeck ’s ( HLUYY ) ( LUN.CO ) second quarter earnings highlights just how big of a role momentum and expectations, reasonable or otherwise, play in stock valuations. Lundbeck’s quarter wasn’t pristine, but it was a beat-and-raise q...
Source: SeekingAlpha
Date: August, 09 2018 17:08
H. Lundbeck A/S ADR 2018 Q2 - Results - Earnings Call Slides
The following slide deck was published by H. Lundbeck A/S ADR in conjunction with their 2018 Q2 earnings Read more ...
Source: SeekingAlpha
Date: August, 08 2018 15:00
H. Lundbeck A/S ADR reports 1H results
H. Lundbeck A/S ADR ( OTCPK:HLUYY ): 1H EPS of DKK13.73 More news on: H. Lundbeck A/S ADR, Earnings news and commentary, Read more ...
Source: SeekingAlpha
Date: August, 08 2018 05:59
Vaccinex Readies $45 Million U.S. IPO
Quick Take Vaccinex ( VCNX ) intends to raise gross proceeds of $45 million from a U.S. IPO, according to an S-1/A registration statement . The firm focuses its efforts on researching and developing biotherapeutics to treat neurodegenerative diseases, cancer, and autoimmune disorders. ...
Source: SeekingAlpha
Date: July, 25 2018 19:38
Lundbeck Finds Its Next CEO, But Finding The Next Spark Could Be Harder
The performance of Danish drugmaker H. Lundbeck A/S ( OTCPK:HLUYY ) ( LUN.CO ) since former CEO Kåre Schultz left for Teva ( TEVA ) would perhaps argue against the idea that drug companies need dynamic CEOs in place to do well – the shares are up about 20% from the time of Sc...
Source: SeekingAlpha
Date: July, 03 2018 10:47
Lundbeck Thriving On Cost Control
Kåre Schultz left H. Lundbeck A/S ( OTCPK:HLUYY ) ( LUN.CO ) to take over as CEO of Teva ( TEVA ) in the fall of 2017, but the man’s legacy as CEO continues to drive strong profit growth at this Danish drugmaker. While Lundbeck continues to benefit from surprisingly strong sale...
Source: SeekingAlpha
Date: May, 09 2018 11:58
H. Lundbeck A/S ADR reports Q1 results
H. Lundbeck A/S ADR ( OTCPK:HLUYY ): Q1 EPS of DKK6.79 More news on: H. Lundbeck A/S ADR, Earnings news and commentary, Read more ...
Source: SeekingAlpha
Date: May, 08 2018 06:38
Lundbeck Gets An Unexpected Boon From The FDA
Things really do seem a little different at the FDA these days. The FDA's commissioner, Scott Gottlieb, has talked openly of wanting the agency to take a different approach to its interactions with the biopharma industry, speeding up processes, removing certain roadblocks, and generally shifti...
Source: SeekingAlpha
Date: May, 04 2018 14:58
TRINTELLIX® (vortioxetine) Prescribing Information Now Includes New Data Showing Improvement in Processing Speed, an Important Aspect of Cognitive Function in Acute Major Depressive Disorder (MDD)
OSAKA, Japan and DEERFIELD, Ill. , May 2, 2018 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda; TSE: 4502) and H. Lundbeck A/S (Lundbeck; LUN.CO, LUN DC, HLUYY) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application for TRI...
Source: PR Newswire
Date: May, 02 2018 17:36

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-0740.33539.76540.4739.5411,301
2018-12-0639.8840.7340.7339.6915,819
2018-12-0540.6439.76541.072539.3714,838
2018-12-0440.6439.76541.072539.3714,838
2018-12-0340.6840.5940.7340.283,399

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-0728811,3012.5484Cover
2018-12-061,08215,6366.9199Cover
2018-12-041,14614,8387.7234Cover
2018-12-035603,39916.4754Cover
2018-11-301,5284,29335.5928Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on HLUYY.


About H. Lundbeck A/S (OTC: HLUYY)

Logo for H. Lundbeck A/S (OTC: HLUYY)

Lundbeck is a global pharmaceutical company highly committed to improving the quality of life for people suffering from brain diseases. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company s products are targeted at diseases such as depression and anxiety, psychotic diseases, epilepsy and Huntington s, Alzheimer s and Parkinson s diseases.

 

Contact Information

 

 

Current Management

  • Ulf Wiinberg / CEO
  • Anders Gotzsche / CFO
  • Magnus Jensen / IR

Current Share Structure

  • Market Cap: $11,081,712,872 - 03/15/2018
  • Issue and Outstanding: 196,136,511 - 12/19/2012

 



Daily Technical Chart for (OTC: HLUYY)

Daily Technical Chart for (OTC: HLUYY)


Stay tuned for daily updates and more on (OTC: HLUYY)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: HLUYY)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in HLUYY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of HLUYY and does not buy, sell, or trade any shares of HLUYY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/